A stabilized variant of the BPC-157 pentadecapeptide sequence optimized for oral and systemic bioavailability.
PDA, or Pentadecapeptide BPC, refers to stabilized analogs of the Body Protection Compound-157 sequence designed to improve pharmacokinetic properties — particularly oral bioavailability and resistance to enzymatic degradation. While BPC-157 itself is remarkably stable for a peptide, various modifications have been explored to further enhance its therapeutic window.
The 'pentadecapeptide' designation refers to the 15-amino acid chain length of the BPC family. Research variants may include D-amino acid substitutions, cyclization, or PEGylation to extend half-life and improve tissue distribution. These analogs maintain the core healing mechanisms of BPC-157 while potentially offering improved pharmacological profiles.
PDA formulations are of particular interest for gastrointestinal applications, where oral delivery is preferred over injection for treating conditions like inflammatory bowel disease, gastric ulcers, and intestinal permeability disorders.
Research on stabilized BPC analogs builds on the extensive BPC-157 preclinical literature. Modified pentadecapeptides have shown comparable or improved tissue healing in animal models of tendon, ligament, and GI tract injuries compared to the parent compound.
Oral bioavailability studies demonstrate that certain BPC analogs survive gastric acid and enzymatic degradation better than native BPC-157, supporting the development of oral formulations for GI-specific applications.
📚 Key Reference: PMID: 24175929 (BPC pentadecapeptide research)
Safety profile expected to be similar to BPC-157 given structural similarity. Limited specific human data on modified variants. Consult your provider.
NOT FDA-approved. Research use only.